Table 3.
Relationship between NNMT expression and the clinical-pathological characteristics of glioma patients from the TCGA GBMLGG cohort data (n = 670).
| Characteristic | Levels | Low Expression of NNMT | High Expression of NNMT | p |
|---|---|---|---|---|
| n | 335 | 335 | ||
| WHO grade, n (%) | G2 | 173 (28.2%) | 43 (7%) | <0.001 |
| G3 | 130 (21.2%) | 107 (17.5%) | ||
| G4 | 0 (0%) | 160 (26.1%) | ||
| IDH status, n (%) | WT | 20 (3%) | 217 (32.8%) | <0.001 |
| Mut | 314 (47.5%) | 110 (16.6%) | ||
| 1p/19q codeletion, n (%) | codel | 145 (21.8%) | 23 (3.5%) | <0.001 |
| Noncodel | 190 (28.6%) | 306 (46.1%) | ||
| Primary therapy outcome, n (%) | PD | 49 (11%) | 54 (12.2%) | <0.001 |
| SD | 96 (21.6%) | 48 (10.8%) | ||
| PR | 39 (8.8%) | 23 (5.2%) | ||
| CR | 105 (23.6%) | 30 (6.8%) | ||
| Gender, n (%) | Female | 145 (21.6%) | 139 (20.7%) | 0.696 |
| Male | 190 (28.4%) | 196 (29.3%) | ||
| Race, n (%) | Asian | 7 (1.1%) | 6 (0.9%) | 0.519 |
| Black or African American | 13 (2%) | 19 (2.9%) | ||
| White | 311 (47.3%) | 302 (45.9%) | ||
| Age, n (%) | ≤60 | 305 (45.5%) | 226 (33.7%) | <0.001 |
| >60 | 30 (4.5%) | 109 (16.3%) | ||
| Histological type, n (%) | Astrocytoma | 99 (14.8%) | 93 (13.9%) | <0.001 |
| Glioblastoma | 0 (0%) | 160 (23.9%) | ||
| Oligoastrocytoma | 87 (13%) | 41 (6.1%) | ||
| Oligodendroglioma | 149 (22.2%) | 41 (6.1%) | ||
| Age, median (IQR) | 39 (32, 50) | 54 (40, 63) | <0.001 |